Evidence synthesis and guideline development in genomic medicine: Current status and future prospects

Genetics in Medicine

Volumn 17, Issue 1, 2015, Pages 63-67

  Schully, Sheri D ^a   Lam, Tram Kim ^a   Dotson, W David ^b   Chang, Christine Q ^a   Aronson, Naomi ^c   Birkeland, Marian L ^d   Brewster, Stephanie Jo ^e   Boccia, Stefania ^f   Buchanan, Adam H ^g   Calonge, Ned ^h   Calzone, Kathleen ^a   Djulbegovic, Benjamin ^i,j   Goddard, Katrina A B ^k   Klein, Roger D ^l   Klein, Teri E ^m   Lau, Joseph ⁿ   Long, Rochelle ^o   Lyman, Gary H ^p   Morgan, Rebecca L ^q   Palmer, Christina G S ^r   Relling, Mary V ^s   Rubinstein, Wendy S ^t   Swen, Jesse J ^u   Terry, Sharon F ^v   Williams, Marc S ^w   Khoury, Muin J ^a,b   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c Blue Cross and Blue Shield Association   (United States)

^d National Comprehensive Cancer Network   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CATHOLIC UNIVERSITY   (Italy)

^g DUKE CANCER INSTITUTE   (United States)

^h Colorado Trust ^*  (United States)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k KAISER PERMANENTE   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m STANFORD UNIVERSITY   (United States)

ⁿ BROWN UNIVERSITY   (United States)

^o NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES   (United States)

^p USA   (United States)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^t NATIONAL INSTITUTES OF HEALTH   (United States)

^u LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^v PXE International   (United States)

^w GEISINGER HEALTH SYSTEM   (United States)

more..

Author keywords

evidence synthesis; genomic medicine; guidelinedevelopment

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CONFLICT OF INTEREST; CONTROLLED STUDY; DATA SYNTHESIS; DISEASE CONTROL; EVIDENCE BASED PRACTICE; GENOMICS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; NATIONAL HEALTH ORGANIZATION; PEER REVIEW; PHARMACOGENETICS; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW (TOPIC); WORKSHOP; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; PROCEDURES; TRENDS;

EVIDENCE-BASED MEDICINE; GENOMICS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84920546044     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.69     Document Type: Article

References (20)

1. Berg JS, Amendola LM, Eng C, et al.; Members of the CSER Actionability and Return of Results Working Group. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med 2013;15:860-867.
2. GAPP Finder. http://www.hugenavigator.net/GAPPKB/topicStartPage.do. Accessed 17 December 2013.
3. Institute of Medicine. Clinical Practice Guidelines We Can Trust. The National Academies Press, Washington, DC, 2011.
4. Gudgeon JM, McClain MR, Palomaki GE, Williams MS. Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet Med 2007;9:473-478.
5. Teutsch SM, Bradley LA, Palomaki GE, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11: 3-14.
6. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W (eds). Human Genome Epidemiology. Oxford University Press: New York, 2004:217-233.
7. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
8. Veenstra DL, Piper M, Haddow JE, et al. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med 2013;15:14-24.
9. Clyne M, Schully SD, Dotson D, et al. Horizon scanning for translational genomic research beyond bench to bedside. Genet Med 2014;16: 535-538.
10. Simone B, De Feo E, Nicolotti N, Ricciardi W, Boccia S. Methodological quality of English-language genetic guidelines on hereditary breast-cancer screening and management: an evaluation using the AGREE instrument. BMC Med 2012;10:143.
11. Gopalakrishna G, Langendam MW, Scholten RJ, Bossuyt PM, Leeflang MM. Guidelines for guideline developers: a systematic review of grading systems for medical tests. Implement Sci 2013;8:78.
12. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014;15:209-217.
13. Green RC, Berg JS, Grody WW, et al.; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-574.
14. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42(Database issue):D980-D985.
15. Ramos EM, Din-Lovinescu C, Berg JS, et al. Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet 2014;166C:93-104.
16. Systematic Review Data Repository (SRDR). http://srdr.ahrq.gov/. Accessed 17 December 2013.
17. Flockhart DA, O'Kane D, Williams MS, et al.; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-150.
18. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92:414-417.
19. Ioannidis JP, Khoury MJ. Are randomized trials obsolete or more important than ever in the genomic era? Genome Med 2013;5:32.
20. Carvajal-Carmona LG, Zauber AG, Jones AM, et al.; APC Trial Collaborators; APPROVe Trial Collaborators; CORGI Study Collaborators; Colon Cancer Family Registry Collaborators; CGEMS Collaborators. Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology 2013;144:53-55.